Related Posts
- Cardiovascular toxicities associated with bispecific T-cell engager therapy
Background Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials…
- 1111 Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC
Background Poly (ADP-ribose) polymerase inhibitor (PARPi) therapy induces DNA damage in tumors to activate cGAS/STING…